Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

281. New Cutoff Point for Platelet Count/Spleen Diameter Ratio to Predict Esophageal Varices in Patients with Hepatitis C Virus-related Hepatic Cirrhosis

New Cutoff Point for Platelet Count/Spleen Diameter Ratio to Predict Esophageal Varices in Patients with Hepatitis C Virus-related Hepatic Cirrhosis 29201712 2018 11 13 2231-5047 5 2 2015 Jul-Dec Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol New Cutoff Point for Platelet Count/Spleen Diameter Ratio to Predict Esophageal Varices in Patients with Hepatitis C Virus-related Hepatic Cirrhosis. 136-137 10.5005/jp-journals-10018-1154 The esophagogastroduodenoscopy (EGD (...) ) with all its hazards remains the gold standard screening tool for esophageal varices. Noninvasive tools have been proposed and studied to replace the EGD. Platelet count (PC)/spleen diameter (SD) ratio as a noninvasive tool for predicting the presence of esophageal varices was proposed and studied in many previous studies. El-Sherbiny W, Elegezy M, Shaltout SW. New Cutoff Point for Platelet Count/ Spleen Diameter Ratio to Predict Esophageal Varices in Patients with Hepatitis C Virus-related Hepatic

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

282. Dynamic of Immune Response induced in Hepatitis B Surface Antigen-transgenic Mice Immunized with a Novel Therapeutic Formulation

Dynamic of Immune Response induced in Hepatitis B Surface Antigen-transgenic Mice Immunized with a Novel Therapeutic Formulation 29201720 2018 11 13 2231-5047 6 1 2016 Jan-Jun Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Dynamic of Immune Response induced in Hepatitis B Surface Antigen-transgenic Mice Immunized with a Novel Therapeutic Formulation. 25-30 10.5005/jp-journals-10018-1161 The development of therapeutic vaccines against chronic hepatitis B requires (...) the capacity of the formulation to subvert a tolerated immune response as well as the evaluation of histopathological damage resulting from the treatment. In the present study, the dynamicity of induced immune response to hepatitis B surface antigen (HBsAg) was evaluated in transgenic mice that constitutively express the HBsAg gene (HBsAg-tg mice). After immunization with a vaccine candidate containing both surface (HBsAg) and core (HBcAg) antigens of hepatitis B virus (HBV), the effect of vaccination

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

283. Past, Present, and Future of Viral Hepatitis in Bangladesh

Past, Present, and Future of Viral Hepatitis in Bangladesh 29201723 2018 11 13 2231-5047 6 1 2016 Jan-Jun Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Past, Present, and Future of Viral Hepatitis in Bangladesh. 43-44 10.5005/jp-journals-10018-1164 Viral hepatitis poses huge burden to the health care delivery system as well as to the economy of Bangladesh. Hepatitis E virus is the leading cause of acute hepatitis in this country, however with the improvement (...) of economic status and sanitation this seems to be on the decline. Hepatitis B virus remains the leading cause in all forms of chronic liver diseases in this country. This virus has been extensively studied in Bangladesh, including from epidemiology to pathogenosis. Clinical trials with innovative therapy conducted in Bangladesh have shown promise. Hepatitis C virus follows hepatitis B virus as the second commonest cause of chronic liver diseases here. However patients in Bangladesh have started

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

284. Viral Hepatitis in Cambodia: Past, Present, and Future

Viral Hepatitis in Cambodia: Past, Present, and Future 29201724 2018 11 13 2231-5047 6 1 2016 Jan-Jun Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Viral Hepatitis in Cambodia: Past, Present, and Future. 45-48 10.5005/jp-journals-10018-1165 The prevalence of viral hepatitis represents Cambodia as 1 of the highest endemic countries in the world. But the prevalence of viral hepatitis B among 5-year-olds is on a decreasing trend due to the effect of nationwide (...) vaccination against hepatitis B. There are key interventions to address viral hepatitis by the Cambodian Ministry of Health. There are so far no comprehensive national guidelines for the prevention, care, and treatment of viral hepatitis. In 2014, the coverage of hepatitis B vaccine at birth and HepB3 vaccine was very high, at 87 and 97% respectively. Other interventions include the screening of viral hepatitis B and C among blood donors; the enhancement of infection prevention and control at health

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

285. Past, Present, and Future of Viral Hepatitis C in Japan

Past, Present, and Future of Viral Hepatitis C in Japan 29201725 2018 11 13 2231-5047 6 1 2016 Jan-Jun Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Past, Present, and Future of Viral Hepatitis C in Japan. 49-51 10.5005/jp-journals-10018-1166 Of all the industrialized countries of the world, Japan has the highest rate of hepatitis C. It also has 1 of the oldest and most varied histories of hepatitis C in the world among the industrialized modern nations. Hepatitis (...) C and its complications are the leading cause of liver cancer in Japan. Japan has the highest rate of liver cancer among the industrialized countries. From 2004 to 2014, PegIFN/RBV treatment was the mainstream of hepatitis C treatment. In 2014, the first interferon-free therapy was approved in Japan. Subsequently, other interferon-free therapies have been approved. Hepatitis C virus disinfection in hepatitis C patients in Japan has become possible with a probability of 96% or more. Yatsuhashi H

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

286. Hepatitis in Malaysia: Past, Present, and Future

Hepatitis in Malaysia: Past, Present, and Future 29201726 2018 11 13 2231-5047 6 1 2016 Jan-Jun Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Hepatitis in Malaysia: Past, Present, and Future. 52-55 10.5005/jp-journals-10018-1167 Malaysia is multiethnic, with a population of 31,127,247 comprising a mixture of Malays (50.1%), Chinese (22.6%), Indians (6.7%), Aborigines (11.8%), others (0.7%), and noncitizens (8.2%). Like other countries in the region, viral (...) hepatitis is an important public health problem in Malaysia. The 3 most common causes for hepatitis in Malaysia are hepatitis A, B, and C. Hepatitis A has been a reportable disease in Malaysia since 1988. Due to the introduction of government control programs, the national incidence rate has dropped steadily. It is now estimated that 50% of Malaysians less than 30 years of age do not have antibodies to hepatitis A and are therefore susceptible to the disease, which can be prevented by reinforcing

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

287. Viral Hepatitis in Mongolia: Past, Present, and Future

Viral Hepatitis in Mongolia: Past, Present, and Future 29201727 2018 11 13 2231-5047 6 1 2016 Jan-Jun Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Viral Hepatitis in Mongolia: Past, Present, and Future. 56-58 10.5005/jp-journals-10018-1168 Viral hepatitis is one of the major health concerns worldwide, particularly in Asian countries. Mongolia, which is located in northern Asia, between Russia and China, is confronting various infectious diseases, such as viral (...) hepatitis and tuberculosis. As for healthy individuals in Mongolia, the reported prevalence of hepatitis B surface antigen (HBsAg) was 9 or 10% and the reported prevalence of anti-hepatitis C virus ranged from 11 to 25%. We reported a markedly high prevalence of hepatitis D virus RNA (83%) among apparently healthy individuals with HBsAg in Ulaanbaatar. Also due to lack of proper mechanisms to handle sewerage, disinfection, and lack of clean water supply across the country, hepatitis A is endemic

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

288. Viral Hepatitis in Nepal: Past, Present, and Future

Viral Hepatitis in Nepal: Past, Present, and Future 29201728 2018 11 13 2231-5047 6 1 2016 Jan-Jun Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Viral Hepatitis in Nepal: Past, Present, and Future. 59-61 10.5005/jp-journals-10018-1169 Over the last four decades, the diagnosis and therapy of viral hepatitis has evolved substantially all over the world. Although Nepal is a developing nation, it has been keeping pace with these developments in terms (...) of the implementation of diagnostic and therapeutic strategies. However, because of a lack of infrastructure and logistics, Nepal still depends on its neighboring countries for molecular diagnostics in viral hepatitis B and C. Though most of the recent antivirals for hepatitis B and directly acting antivirals for hepatitis C are available at a highly subsidized cost, affordability still remains an issue. A lack of comprehensive national program for hepatitis B and C has been a major barrier for access to health

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

289. Viral Hepatitis in Korea: Past, Present, and Future

Viral Hepatitis in Korea: Past, Present, and Future 29201729 2018 11 13 2231-5047 6 1 2016 Jan-Jun Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Viral Hepatitis in Korea: Past, Present, and Future. 62-64 10.5005/jp-journals-10018-1170 Korea has been one of the endemic areas of hepatitis B virus (HBV; exclusively genotype C) infection since ancient times. The epidemiology of HBV in Korea is easily expected to have changed over the last two decades owing to the high (...) coverage rate of universal HBV vaccination. The main mode of hepatitis C virus (HCV) infection may have been effectively blocked since 1992 when compulsory blood screening for anti-HCV was implemented, and consequently, the prevalence of anti-HCV is also expected to have markedly decreased during the last two decades. This review will briefly describe what really happened during the last couple of decades in the epidemiology of HBV and HCV and in the incidence and mortality rates of liver cirrhosis

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

290. Viral Hepatitis in Indonesia: Past, Present, and Future

Viral Hepatitis in Indonesia: Past, Present, and Future 29201730 2018 11 13 2231-5047 6 1 2016 Jan-Jun Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Viral Hepatitis in Indonesia: Past, Present, and Future. 65-69 10.5005/jp-journals-10018-1171 Since Indonesia is a huge archipelago country, the prevalence of hepatitis virus infection highly varies among islands. In average the prevalence of clinical hepatitis in Indonesia was 0.6% in the year 2007. Of 82 clinical (...) acute hepatitis patients treated in hospitals in several cities, acute hepatitis A accounted for 28.0%, acute hepatitis B 13.4%, and acute hepatitis C 1.2%; 35.4% patients were infected by unknown etiology. In 1980s, the prevalence of anti-HAV in the age group 10- to 14-years was almost 100% in smaller towns and 45 to 60% in big cities. About 30 years later, anti-HAV prevalence decreased to around 13% in the same smaller town. Outbreaks of hepatitis A were reported between 2006 and 2009 in several

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

291. Viral Hepatitis in Pakistan: Past, Present, and Future

Viral Hepatitis in Pakistan: Past, Present, and Future 29201731 2018 11 13 2231-5047 6 1 2016 Jan-Jun Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Viral Hepatitis in Pakistan: Past, Present, and Future. 70-81 10.5005/jp-journals-10018-1172 Viral hepatitis is a major cause of morbidity and mortality worldwide and a rising cause for concern in Asian countries. Weather it is blood borne or water/food borne hepatotropic virus, increasing burden is alarming for Asian (...) countries. In this review we have evaluated the existing data to estimate the burden of viral hepatitis in populations of all age groups nationwide, along with an assessment of the risk factors and preventive and management strategies currently employed in Pakistan. The aim of our work is to consolidate and supplement the present knowledge regarding viral hepatitis in light of past and present trends and to provide future direction to the existing health policies. Butt AS, Sharif F. Viral Hepatitis

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

292. A Hepatocellular Carcinoma Case in a Patient Who had Immunity to Hepatitis B Virus Earlier

A Hepatocellular Carcinoma Case in a Patient Who had Immunity to Hepatitis B Virus Earlier 29201732 2018 11 13 2231-5047 6 1 2016 Jan-Jun Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol A Hepatocellular Carcinoma Case in a Patient Who had Immunity to Hepatitis B Virus Earlier. 82-83 10.5005/jp-journals-10018-1173 Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. Hepatitis B virus infection is one of the most important etilogical factors (...) of HCC. In this case report, a patient with HCC previously infected and having ongoing immunity against hepatitis B virus will be discussed. Ates I, Kaplan M, Demirci S, Altiparmak E. A Hepatocellular Carcinoma Case in a Patient Who had Immunity to Hepatitis B Virus Earlier. Euroasian J Hepato-Gastroenterol 2016;6(1):82-83. Ates Ihsan I Department of Internal Medicine, Ankara Numune Education and Research Hospital, Sihhiye, Ankara, Turkey. Kaplan Mustafa M Department of Internal Medicine, Ankara

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

293. Interstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment in a Patient with Chronic Hepatitis C

Interstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment in a Patient with Chronic Hepatitis C 29201735 2018 11 13 2231-5047 6 1 2016 Jan-Jun Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Interstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment in a Patient with Chronic Hepatitis C. 91-92 10.5005/jp-journals-10018-1176 Alkan E, Akin M, Adanir H, Tuna Y. Interstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment (...) in a Patient with Chronic Hepatitis C. Euroasian J Hepato-Gastroenterol 2016;6(1):91-92. Alkan Erhan E Department of Gastroenterology, Burdur State Hospital, Burdur, Turkey. Akin Mete M Department of Gastroenterology, Akdeniz University School of Medicine, Antalya, Turkey. Adanir Haydar H Department of Gastroenterology, Diyarbakir Training and Research Hospital Gastroenterology Clinic, Diyarbakir, Turkey. Tuna Yasar Y Department of Gastroenterology, Akdeniz University Faculty of Medicine, Antalya, Turkey

Euroasian journal of hepato-gastroenterology2016 Full Text: Link to full Text with Trip Pro

294. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.

The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. BACKGROUND: With recent improvements in vaccines and treatments against viral hepatitis, an improved understanding of the burden of viral hepatitis is needed to inform global intervention strategies. We used data from the Global Burden of Disease (GBD) Study to estimate morbidity and mortality for acute viral hepatitis, and for cirrhosis and liver cancer caused by viral hepatitis (...) , by age, sex, and country from 1990 to 2013. METHODS: We estimated mortality using natural history models for acute hepatitis infections and GBD's cause-of-death ensemble model for cirrhosis and liver cancer. We used meta-regression to estimate total cirrhosis and total liver cancer prevalence, as well as the proportion of cirrhosis and liver cancer attributable to each cause. We then estimated cause-specific prevalence as the product of the total prevalence and the proportion attributable

Lancet2016

295. Analysis of the Variability of Epstein-Barr Virus Genes in Infectious Mononucleosis: Investigation of the Potential Correlation with Biochemical Parameters of Hepatic Involvement

Analysis of the Variability of Epstein-Barr Virus Genes in Infectious Mononucleosis: Investigation of the Potential Correlation with Biochemical Parameters of Hepatic Involvement 28356886 2018 11 13 1452-8258 35 3 2016 Sep Journal of medical biochemistry J Med Biochem Analysis of the Variability of Epstein-Barr Virus Genes in Infectious Mononucleosis: Investigation of the Potential Correlation with Biochemical Parameters of Hepatic Involvement. 337-346 10.1515/jomb-2015-0021 Primary Epstein (...) -Barr virus (EBV) infection is usually asymptomatic, although at times it results in the benign lymphoproliferative disease, infectious mononucleosis (IM), during which almost half of patients develop hepatitis. The aims of the present study are to evaluate polymorphisms of EBV genes circulating in IM isolates from this geographic region and to investigate the correlation of viral sequence patterns with the available IM biochemical parameters. The study included plasma samples from 128 IM patients

Journal of medical biochemistry2016 Full Text: Link to full Text with Trip Pro

296. Sofosbuvir, GS-9857 and velpatasvir triple therapy for chronic hepatitis C

Sofosbuvir, GS-9857 and velpatasvir triple therapy for chronic hepatitis C Sofosbuvir, GS-9857 and velpatasvir triple therapy for chronic hepatitis C Sofosbuvir, GS-9857 and velpatasvir triple therapy for chronic hepatitis C NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Sofosbuvir, GS-9857 and velpatasvir triple (...) therapy for chronic hepatitis C. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Hepatitis C is a virus that causes inflammation of the liver. The virus is present in the blood of people with the infection, and this can infect others that come into contact with it. The virus is most commonly passed on by needles contaminated with infected blood, but it is also spread occasionally through unprotected sex. Most people with hepatitis C

Health Technology Assessment (HTA) Database.2016

297. Lupus-Like Immune Complex-Mediated Glomerulonephritis in Patients With Hepatitis C Virus Infection Treated With Oral, Interferon-Free, Direct-Acting Antiviral Therapy

Lupus-Like Immune Complex-Mediated Glomerulonephritis in Patients With Hepatitis C Virus Infection Treated With Oral, Interferon-Free, Direct-Acting Antiviral Therapy 27990496 2018 11 13 2468-0249 1 3 2016 Sep Kidney international reports Kidney Int Rep Lupus-like Immune Complex-mediated Glomerulonephritis in Patients with Hepatitis C Virus Infection Treated with Oral, Interferon-free, Direct-acting Antiviral Therapy. 135-143 Novel, all-oral interferon-free direct-acting antiviral agents have (...) revolutionized the management of hepatitis C virus (HCV) infection by producing exceptional cure rates with minimal adverse events. While provocation or exacerbation of autoimmunity has been reported in HCV-infected patients receiving interferon, this phenomenon has not been reported in patients receiving interferon-free HCV therapy. We report the occurrence of three cases of lupus-like immune complex-mediated glomerulonephritis occurring shortly after exposure to sofosbuvir-based direct-acting antiviral

Kidney international reports2016 Full Text: Link to full Text with Trip Pro

298. Cortical blindness induced by hepatic encephalopathy: case report and review of published case reports

Cortical blindness induced by hepatic encephalopathy: case report and review of published case reports 29123845 2018 11 13 2052-8817 4 1 2017 01 Acute medicine & surgery Acute Med Surg Cortical blindness induced by hepatic encephalopathy: case report and review of published case reports. 109-113 10.1002/ams2.225 Cortical blindness induced by hepatic encephalopathy is an extremely rare complication and its epidemiology has not been studied in great detail. We report a 63-year-old man with liver (...) cirrhosis who developed sudden bilateral visual impairment. On arrival at hospital, the patient had orientation disturbance, slurred speech, and mild disturbance of consciousness with impaired vision (light sense). He had no focal neurological deficits except for bilateral blindness. Cerebral stroke was suspected, but imaging and ophthalmological examination did not reveal major abnormalities. An increased concentration of ammonia in blood suggested hepatic encephalopathy; a diagnosis of cortical

Acute medicine & surgery2016 Full Text: Link to full Text with Trip Pro

299. Screening and Treatment for Patients with NS5A Resistance-Associated Variants of Hepatitis C Virus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Screening and Treatment for Patients with NS5A Resistance-Associated Variants of Hepatitis C Virus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Screening and Treatment for Patients with NS5A Resistance-Associated Variants of Hepatitis C Virus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Screening and Treatment for Patients with NS5A Resistance-Associated Variants of Hepatitis C Virus: A Review (...) of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Screening and Treatment for Patients with NS5A Resistance-Associated Variants of Hepatitis C Virus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Published on: June 27, 2016 Project Number: RC0788-000 Product Line: Research Type: Other Diagnostics Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of hepatitis C pharmacotherapies containing NS5A inhibitors

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

300. Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B

Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B 27504160 2016 08 09 2018 11 13 2008-5842 8 6 2016 Jun Electronic physician Electron Physician Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B. 2466-74 10.19082 (...) /2466 The mutational pattern of chronic Hepatitis B virus (HBV) is unclear in patients who show incomplete response to antiviral therapy. The aims of this study were 1) to determine the benefit of combination therapy with adefovir dipivoxil (ADV) and Lamivudine (LAM) versus ADV or LAM alone in maintaining virological, biochemical and histological responses and 2) to investigate the patterns of mutations in the reverse transcriptase and surface proteins of HBV with LAM and/or ADF-resistant

Electronic physician2016 Full Text: Link to full Text with Trip Pro